rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DMAC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      DiaMedica Therapeutics: Maintaining 'Buy' DM199 FGR Data November 2026 And AIS Advancement

      Analyst rates DiaMedica Therapeutics a Buy: ReMEDy2's Q1 2027 interim could prompt a stop on strong efficacy; Nov.

      Nov 16Seeking AlphaDMAC
      DiaMedica Therapeutics Q3 Earnings Call Highlights
      Nov 13Yahoo FinanceDMAC
      Earnings call transcript: DiaMedica meets Q3 2026 EPS view as trial milestones build
      Nov 13Investing.comDMAC
      DiaMedica Therapeutics Inc. Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinanceDMAC
      DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
      Nov 5Yahoo FinanceDMAC
      DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

      MINNEAPOLIS, October 19, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on Tuesday, November 24, 2026, at 8:00am Eastern Time.

      Oct 19Yahoo FinanceDMAC
      DiaMedica to host event on fetal growth restriction treatment
      Sep 30Investing.comDMAC
      H.C. Wainwright Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)

      Detailed price information for Diamedica Therapeutics Inc (DMAC-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailDMAC
      DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

      MINNEAPOLIS, September 02, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.

      Sep 2Yahoo FinanceDMAC
      Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet

      The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Aug 26Yahoo FinanceDMAC

      This is the newest page. Registered accounts read further back.